READER SERVICE |
EDUCATION |
Learning With Newsweek |
Newsweek Home » Society |
Andrea Modica for Newsweek |
Most Popular |
| |||||
BLOG TALK |
Read what bloggers are saying about this Newsweek article |
June 13 issue - Donald Elbel remembers sneaking into the garage as a 10-year-old to steal beers from his dad's cooler. By the time he was 40 and working as a mechanic in Kendalia, Texas, Elbel was chugging 35 Lone Stars a day. He knew his life was in danger—he once slammed his car into a telephone pole at 80 miles an hour and, after a short detour to the hospital, ended up in jail. He tried everything from Alcoholics Anonymous to hospital detox, but he couldn't give up the brew. Then, in 1998, Elbel volunteered for a clinical trial of a drug called topiramate, a well-known seizure medication. He wasn't required to stay sober, but after a few days of oral medication, he lost interest in drinking. "I went around at first saying 'Something's missing,' but I didn't know what," says Elbel. "The doctors had to tell me I was missing the craving." Though he took the drug for only three months, Elbel hasn't touched a beer in seven years.
It sounds like magic, but over the past decade scientists have come to better understand how the addicted brain works. And they are using that knowledge to study several existing drugs as potential treatments for the millions enslaved by their cravings. The leading candidate may be topiramate, known commercially as Topamax. For years, epileptic patients reported that it helped them fight food cravings and lose weight. Now, in addition to helping alcoholics, the drug shows promise in early studies with binge eaters, smokers and even gamblers. Because these drugs have a record of safety, doctors may legally use them to treat addiction long before they are officially approved for that purpose, a practice known as off-label prescribing.
Addiction is a kind of brain damage. In a normal brain, a neurotransmitter called glutamate is released when a person experiences desire. It's essentially a "go" signal. Counteracting glutamate is a neurotransmitter called GABA (gamma-aminobutyric acid), an inhibitor that keeps glutamate and other go signals from overwhelming us. The strength of a craving depends on the balance of glutamate and GABA in the brain. When an addict confronts a martini or cigarette, theory has it, GABA is overwhelmed by glutamate—desire trumps inhibition. The brain then becomes flooded with dopamine, our master pleasure chemical, reinforcing the original desire.
Topiramate works on both ends of the GABA-glutamate seesaw: it reduces the release of glutamate and enhances the release of GABA. In the Texas study Elbel took part in, 17 percent of hard-core drinkers stayed dry for at least a month while taking the drug. An additional 20 percent cut back from heavy consumption to more normal levels. The drug does have side effects, most commonly mental fuzziness, but patients tend to stick with it, says study author Bankole Johnson of the University of Virginia. A multisite study to confirm his findings is underway.